search
Back to results

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Primary Purpose

Non-Hodgkin Lymphoma

Status
Recruiting
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
CD19x22 CAR T Cells
Sponsored by
University of Colorado, Denver
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Non-Hodgkin Lymphoma focused on measuring Relapsed, Refractory

Eligibility Criteria

16 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Age: ≥ 16 years of age with no upper age limit. (NOTE: the first three subjects on this trial must be ≥ 18 years of age.)
  2. Histologically confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008:

    1. Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR
    2. Primary mediastinal (thymic) large B cell lymphoma; OR
    3. Transformation to DLBCL will also be included.
    4. Subjects must not have signs or symptoms of CNS disease or detectable evidence of CNS disease on magnetic resonance imaging (MRI) at screening; subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible.
  3. Subjects must have progressed, had stable disease, or recurred after two lines of therapies including an anthracycline and an anti-CD20 monoclonal antibody.
  4. Must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma;26 lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy.
  5. Subjects who have undergone autologous stem cell transplantation (SCT) with disease progression or relapse are eligible.
  6. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, are:

    1. At least 100 days post-transplant,
    2. Do not have graft versus host disease (GVHD)
  7. At least 14 days or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy (including radiation therapy) at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives.
  8. At least 7 days must have elapsed since any prior steroid use (dexamethasone or prednisone) prior to apheresis. Physiological replacement doses are allowable with no washout period. Topical or inhaled steroids for localized GVHD is allowable.
  9. Peripheral blood CD3 count must be >0.15 x 10^6 cells/mL within 14 days prior to proceeding with apheresis.
  10. Toxicities from prior therapy must be stable and recovered to ≤ grade 1 (except for clinically non-significant toxicities such as alopecia).
  11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or Karnofsky ≥ 80%.
  12. Adequate organ function as defined by:

    1. Absolute neutrophil count (ANC) ≥ 750/μL.
    2. Platelet count ≥ 50,000/ μL.
    3. Renal: Creatinine ≤ 2 mg/dL OR creatinine clearance (as estimated by Cockcroft Gault equation) ≥ 60 mL/min.
    4. Hepatic: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 upper limit of normal (ULN).
    5. Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome where a bilirubin <3.0 will be acceptable.
    6. Cardiac: Ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings.
    7. Pulmonary: No clinically significant pleural effusion.

1. Baseline oxygen saturation > 92% on room air and; 2. Pulmonary Function Test: Diffuse capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) are all ≥50% of predicted by spirometry after correcting for hemoglobin.

13. Females of childbearing potential must have a negative serum pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential).

14. Subjects of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen; females of childbearing potential must have a negative pregnancy test.

15. Must be able to give informed consent; subjects unable to give informed consent will not be eligible for this study.

16. Be able to consent to long-term follow-up protocol (#20-0188).

Exclusion Criteria:

Subjects meeting any of the following criteria are not eligible for participation in the study.

  1. Age < 16 years of age.
  2. Previous CAR T therapy (Phase 1 only).
  3. Signs or symptoms of active CNS disease or detectable evidence of CNS disease on MRI at the time of screening. Subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible.
  4. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease free for at least 3 years.
  5. Uncontrolled fungal, bacterial, viral, or other infection requiring antimicrobials for management; simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment.
  6. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (hepatitis B surface antigen [HBsAg] positive) or hepatitis C.

8. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment or have cardiac atrial or cardiac ventricular lymphoma involvement.

9. Venous thrombosis or embolism not managed on a stable regimen of anticoagulation.

10. Any medical condition that in the judgement of the sponsor is likely to interfere with assessment of safety or efficacy of study treatment.

11. History of severe immediate hypersensitivity reaction to any of the agents used in this study.

12. Pregnancy (serum pregnancy test must be obtained at time of enrollment for females of childbearing potential and to be repeated 72 hours prior to lymphodepleting chemotherapy regimen); females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be childbearing potential.

13. Lactating. 14. In the investigator's judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation.

15. May not have primary immunodeficiency or history of autoimmune disease (e.g., Crohn's Disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years.

16. Unwilling to participate in long-term follow-up protocol that is required if CAR T cell therapy is administered at CU-AMC (#20-0188).

Sites / Locations

  • University of Colorado HospitalRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CD19x22 CAR T Cell Infusion

Arm Description

Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells

Outcomes

Primary Outcome Measures

Phase 1: Overall Tolerability of CD19x22 CAR T Therapy in CAR-naive Subjects as Assessed by Type, Frequency, and Severity of Adverse Events (AEs)
All AEs, including laboratory abnormalities, will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading criteria.
Phase 1: Determine the Phase 1b Dose Level
Incidence and frequency of Grade 3-5 toxicity occurring within the dose limiting toxicity (DLT) period post CD19x22 CAR T infusion. Grades 3-5 adverse events (AEs) are defined as Severe, Life-Threatening, and Fatal.
Phase 1b: Establish Evidence of Tolerability of CD19x22 CAR T Cells in a Broader Sample of CAR-naive Subjects Versus Those who have Previously Received CD19 CAR T Cell Therapy
Frequency and severity of all adverse events (AEs) and serious adverse events (SAEs). All AEs and SAEs will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading criteria.
Phase 1b: Evaluate the Clinical Efficacy of CD19x22 CAR T through Calculating Proportion of CR, PR, SD, and PD.
Efficacy of treatment will be quantified by calculating the proportion of subjects who achieved a response, such as a complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) at Day +90, 6 months, and 1 year.
Phase 1b: Evaluate the Clinical Efficacy of CD19x22 CAR T through Reporting ORR, PFS, DOR, and OS
Reporting of overall response rate (ORR), progression free survival (PFS), duration of response (DOR), and overall survival (OS) at 1 year.

Secondary Outcome Measures

Percentage of Patients for Whom the Desired Dose of CAR T Cells was Successfully Produced
The feasibility of manufacturing the desired dose of anti-CD19x22 CAR T cells will be established using the percentage of patients for whom the desired dose of CAR T cells was successfully produced.
Evaluate Clinical Efficacy of CD19x22 CAR T
Clinical efficacy is defined through Lugano response criteria at Day +90, 6 months, and 1 year. Efficacy in the phase 1b portion will be stratified based on prior receipt of CD19 CAR T cell therapy.
Percentage of Study Participants who Receive CD19x22 CAR T Cell Infusion without Infusion Reaction

Full Information

First Posted
October 6, 2021
Last Updated
March 24, 2023
Sponsor
University of Colorado, Denver
search

1. Study Identification

Unique Protocol Identification Number
NCT05098613
Brief Title
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
Official Title
Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients With Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 21, 2021 (Actual)
Primary Completion Date
December 2024 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Colorado, Denver

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This open-label, single arm phase 1/1b trial aims to determine the safety and tolerability of anti-CD19 and anti-CD22 chimeric antigen receptor-expressing (CAR) T cells (CD19x22 CAR T) in adolescents and adults with relapsed/refractory (R/R) B-cell Non-Hodgkin Lymphoma (B-NHL). Phase 1 will determine the maximum tolerated dose of CD19x22 CAR T cells using a standard 3+3 trial design. Phase 1b is an expansion phase designed to evaluate the preliminary efficacy of CD19x22 CAR T in CAR-treated and CAR-naïve patients.
Detailed Description
Phase 1: To determine the safety and tolerability of infusing CD19x22 CAR T, generated using a bicistronic vector, in adolescents and adults with R/R B-NHL, and to determine the Phase 1b recommended dose. Phase 1b (expansion phase): To acquire additional evidence of safety and efficacy of-CD19x22 CAR T infusion in CAR-treated and CAR-naïve R/R B-NHL patients. Secondary objectives for all subjects in Phase 1 and Phase 1b include: 1) Feasibility of manufacturing and infusion, 2) Safety of infusion and 3) Efficacy: Descriptive characterization of complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) at Day +90. As well, progression-free survival (PFS), overall survival (OS), duration of remission (DOR) and overall response rate (ORR) will be determined. Efficacy will be descriptively stratified based on prior receipt of CAR-T cell therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Non-Hodgkin Lymphoma
Keywords
Relapsed, Refractory

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
The study is a prospective single arm Phase 1/1b with four dose levels. Phase 1 will be the dose finding phase aimed at determining the maximum tolerated dose using a standard 3+3 dose-escalation strategy. Phase 1b will be an expansion phase designed to evaluate the clinical activity of CD19x22 CAR T in CD19 CAR-treated and CAR-naïve B-NHL patients at the maximum tolerated dose.
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CD19x22 CAR T Cell Infusion
Arm Type
Experimental
Arm Description
Lymphodepleting chemotherapy following by infusion of CD19x22 CAR T Cells
Intervention Type
Drug
Intervention Name(s)
CD19x22 CAR T Cells
Intervention Description
Autologous peripheral blood mononuclear cells transduced with CD19x22 CAR T lentiviral vector.
Primary Outcome Measure Information:
Title
Phase 1: Overall Tolerability of CD19x22 CAR T Therapy in CAR-naive Subjects as Assessed by Type, Frequency, and Severity of Adverse Events (AEs)
Description
All AEs, including laboratory abnormalities, will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading criteria.
Time Frame
12 Months Post Infusion
Title
Phase 1: Determine the Phase 1b Dose Level
Description
Incidence and frequency of Grade 3-5 toxicity occurring within the dose limiting toxicity (DLT) period post CD19x22 CAR T infusion. Grades 3-5 adverse events (AEs) are defined as Severe, Life-Threatening, and Fatal.
Time Frame
30 Days Post Infusion
Title
Phase 1b: Establish Evidence of Tolerability of CD19x22 CAR T Cells in a Broader Sample of CAR-naive Subjects Versus Those who have Previously Received CD19 CAR T Cell Therapy
Description
Frequency and severity of all adverse events (AEs) and serious adverse events (SAEs). All AEs and SAEs will be graded using the National Cancer Institute's (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 grading criteria.
Time Frame
12 Months Post Infusion
Title
Phase 1b: Evaluate the Clinical Efficacy of CD19x22 CAR T through Calculating Proportion of CR, PR, SD, and PD.
Description
Efficacy of treatment will be quantified by calculating the proportion of subjects who achieved a response, such as a complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD) at Day +90, 6 months, and 1 year.
Time Frame
12 Months Post Infusion
Title
Phase 1b: Evaluate the Clinical Efficacy of CD19x22 CAR T through Reporting ORR, PFS, DOR, and OS
Description
Reporting of overall response rate (ORR), progression free survival (PFS), duration of response (DOR), and overall survival (OS) at 1 year.
Time Frame
12 Months Post Infusion
Secondary Outcome Measure Information:
Title
Percentage of Patients for Whom the Desired Dose of CAR T Cells was Successfully Produced
Description
The feasibility of manufacturing the desired dose of anti-CD19x22 CAR T cells will be established using the percentage of patients for whom the desired dose of CAR T cells was successfully produced.
Time Frame
Day 0 (Infusion)
Title
Evaluate Clinical Efficacy of CD19x22 CAR T
Description
Clinical efficacy is defined through Lugano response criteria at Day +90, 6 months, and 1 year. Efficacy in the phase 1b portion will be stratified based on prior receipt of CD19 CAR T cell therapy.
Time Frame
12 Months Post Infusion
Title
Percentage of Study Participants who Receive CD19x22 CAR T Cell Infusion without Infusion Reaction
Time Frame
30 Days Post Infusion

10. Eligibility

Sex
All
Minimum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age: ≥ 16 years of age with no upper age limit. (NOTE: the first three subjects on this trial must be ≥ 18 years of age.) Histologically confirmed aggressive B-cell NHL including the following types defined by World Health Organization (WHO) 2008: Diffuse Large B-Cell Lymphoma (DLBCL) not otherwise specified; T cell/histiocyte rich large B cell lymphoma; DLBCL associated with chronic inflammation; Epstein Barr Virus (EBV)+ DLBCL of the elderly; OR Primary mediastinal (thymic) large B cell lymphoma; OR Transformation to DLBCL will also be included. Subjects must not have signs or symptoms of CNS disease or detectable evidence of CNS disease on magnetic resonance imaging (MRI) at screening; subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible. Subjects must have progressed, had stable disease, or recurred after two lines of therapies including an anthracycline and an anti-CD20 monoclonal antibody. Must have evaluable or measurable disease according to the revised International Working Group (IWG) Response Criteria for Malignant Lymphoma;26 lesions that have been previously irradiated will be considered measurable only if progression has been documented following completion of radiation therapy. Subjects who have undergone autologous stem cell transplantation (SCT) with disease progression or relapse are eligible. Subjects who have undergone allogeneic SCT will be eligible if, in addition to meeting other eligibility criteria, are: At least 100 days post-transplant, Do not have graft versus host disease (GVHD) At least 14 days or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy (including radiation therapy) at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives. At least 7 days must have elapsed since any prior steroid use (dexamethasone or prednisone) prior to apheresis. Physiological replacement doses are allowable with no washout period. Topical or inhaled steroids for localized GVHD is allowable. Peripheral blood CD3 count must be >0.15 x 10^6 cells/mL within 14 days prior to proceeding with apheresis. Toxicities from prior therapy must be stable and recovered to ≤ grade 1 (except for clinically non-significant toxicities such as alopecia). Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, or Karnofsky ≥ 80%. Adequate organ function as defined by: Absolute neutrophil count (ANC) ≥ 750/μL. Platelet count ≥ 50,000/ μL. Renal: Creatinine ≤ 2 mg/dL OR creatinine clearance (as estimated by Cockcroft Gault equation) ≥ 60 mL/min. Hepatic: Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) ≤ 2.5 upper limit of normal (ULN). Total bilirubin ≤ 1.5 mg/dL, except in subjects with Gilbert's syndrome where a bilirubin <3.0 will be acceptable. Cardiac: Ejection fraction ≥ 45%, no evidence of physiologically significant pericardial effusion as determined by an echocardiogram (ECHO), and no clinically significant electrocardiogram (ECG) findings. Pulmonary: No clinically significant pleural effusion. 1. Baseline oxygen saturation > 92% on room air and; 2. Pulmonary Function Test: Diffuse capacity of the lungs for carbon monoxide (DLCO), forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) are all ≥50% of predicted by spirometry after correcting for hemoglobin. 13. Females of childbearing potential must have a negative serum pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential). 14. Subjects of childbearing or child-fathering potential must be willing to practice birth control from the time of enrollment on this study and for four (4) months after receiving the preparative regimen; females of childbearing potential must have a negative pregnancy test. 15. Must be able to give informed consent; subjects unable to give informed consent will not be eligible for this study. 16. Be able to consent to long-term follow-up protocol (#20-0188). Exclusion Criteria: Subjects meeting any of the following criteria are not eligible for participation in the study. Age < 16 years of age. Previous CAR T therapy (Phase 1 only). Signs or symptoms of active CNS disease or detectable evidence of CNS disease on MRI at the time of screening. Subjects who have been previously treated for CNS disease, but have no evidence of disease at screening are eligible. History of malignancy other than non-melanoma skin cancer or carcinoma in situ (e.g., cervix, bladder, breast) unless disease free for at least 3 years. Uncontrolled fungal, bacterial, viral, or other infection requiring antimicrobials for management; simple urinary tract infection (UTI) and uncomplicated bacterial pharyngitis are permitted if responding to active treatment. Known history of infection with human immunodeficiency virus (HIV) or hepatitis B (hepatitis B surface antigen [HBsAg] positive) or hepatitis C. 8. History of myocardial infarction, cardiac angioplasty or stenting, unstable angina, or other clinically significant cardiac disease within 12 months of enrollment or have cardiac atrial or cardiac ventricular lymphoma involvement. 9. Venous thrombosis or embolism not managed on a stable regimen of anticoagulation. 10. Any medical condition that in the judgement of the sponsor is likely to interfere with assessment of safety or efficacy of study treatment. 11. History of severe immediate hypersensitivity reaction to any of the agents used in this study. 12. Pregnancy (serum pregnancy test must be obtained at time of enrollment for females of childbearing potential and to be repeated 72 hours prior to lymphodepleting chemotherapy regimen); females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be childbearing potential. 13. Lactating. 14. In the investigator's judgment, the subject is unlikely to complete all protocol required study visits or procedures, including follow up visits, or comply with the study requirements for participation. 15. May not have primary immunodeficiency or history of autoimmune disease (e.g., Crohn's Disease, rheumatoid arthritis, systemic lupus) resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years. 16. Unwilling to participate in long-term follow-up protocol that is required if CAR T cell therapy is administered at CU-AMC (#20-0188).
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Derek Schatz
Phone
7208480628
Email
derek.schatz@cuanschutz.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Benjamin Echalier
Phone
3038485523
Email
benjamin.echalier@cuanschutz.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manali Kamdar, MD
Organizational Affiliation
University of Colorado, Denver
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Colorado Hospital
City
Aurora
State/Province
Colorado
ZIP/Postal Code
80045
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Manali Kamdar, MD
Phone
720-848-0752
Email
manali.kamdar@cuanschutz.edu

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

We'll reach out to this number within 24 hrs